TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9597563
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine suppositories (MSC-R)
Study: 9597563
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine tablets (MSC-T)
Study: 29705451
Drug: Barberry juice
Normalized name: bilberry juice extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barberry juice (BJ), 200 ml daily for 8 weeks
Study: 28006831
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (melt and tablets)
Study: 26037429
Drug: Double-fortified salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-fortified salt (DFS) containing 47 mg of potassium iodate and 3300 mg of microencapsulated ferrous fumarate (1100 mg elemental iron) per kg of salt
Study: 16788299
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose ASA+MR-DP (b.i.d. on days 5-28)
Study: 16788299
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose ASA+MR-DP (once daily before bed during days 5-14, b.i.d. on days 15-28)
Study: 15299060
Drug: Acetazolamide (ACZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACZ) administered intravenously at a dosage of 1 g
Study: 15299060
Drug: Continuous-infusion H(2)(15)O
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion H(2)(15)O PET
Study: 9354317
Drug: Tedisamil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedisamil (100 mg twice daily)
Study: 2656775
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg twice daily)
Study: 9354317
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Tedisamil and Atenolol
Study: 9354317
Drug: Tedisamil alone
Normalized name: tedisamil
DrugBank: Tedisamil (DB06200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedisamil alone and in combination with Atenolol
Study: 8308936
Drug: Buspirone 10
Normalized name: busPIRone 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 10 mg t.i.d.
Study: 8308936
Drug: Placebo 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg t.i.d.
Study: 29725790
Drug: Active, Linkage,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active, Linkage, Engagement, Retention and Treatment (ALERT) specialist for outreach and health coaching
Study: 22947269
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment supported by self‐monitoring (pro‐active counseling, pedometer, weighing scale, blood pressure device)
Study: 22947269
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without self‐monitoring
Study: 22947269
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment supported by self‐monitoring
Study: 1204278
Drug: Nabilone 1
Normalized name: nabilone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone 1 mg
Study: 7569458
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg od plus amoxicillin 500 mg tid (group A)
Study: 7569458
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate 260 mg bid, metronidazole 250 mg tid and amoxicillin 500 mg tid (group B)
Study: 1943411
Drug: Hypercaloric parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypercaloric parenteral nutrition
Study: 1943411
Drug: Hypocaloric parenteral
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric parenteral nutrition
Study: 7026255
Drug: Captopril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (1 mg/kg body weight)
Study: 30664267
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF), 12 doses of 300 μg each in 28 days
Study: 28508697
Drug: Topical estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estrogen (GI)
Study: 28508697
Drug: Topical genistein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical genistein (GII)
Study: 8510706
Drug: Diazepam (0.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.33 mg/kg) administered orally every eight hours during febrile illnesses
Study: 8510706
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally every eight hours during febrile illnesses
Study: 8510706
Drug: Diazepam (in
Normalized name: diazepam (in soybean oil) 5 mg/mL INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (in children who had seizures while receiving the medication)
Study: 8510706
Drug: Diazepam (among
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (among children who took at least one dose)
Study: 3499163
Drug: Fasting and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting and 15 ml aluminium hydroxide gel
Study: 3499163
Drug: Postprandial and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial and 15 ml aluminium hydroxide gel
Study: 3499163
Drug: Fasting and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting and 15 ml aluminium and magnesium hydroxide gel
Study: 3499163
Drug: Postprandial and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial and 15 ml aluminium and magnesium hydroxide gel
Study: 23374879
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise without a clear treatment rationale
Study: 23374879
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise with treatment rationale
Study: 23374879
Drug: Behavioural activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural activation with treatment rationale
Study: 23374879
Drug: Behavioural activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural activation without a clear treatment rationale
Study: 23374879
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control group with delayed treatment
Study: 23374879
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (including relapse prevention program)
Study: 19325484
Drug: Early antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early antifungal therapy
Study: 17543895
Drug: Chronic methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic methylphenidate (MPH) 0.3 mg/kg/dose
Study: 17543895
Drug: Chronic methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic methylphenidate (MPH) 0.6 mg/kg/dose
Study: 8004358
Drug: 2.7 g
Normalized name: Magnesium 420 MG/2.7 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.7 g 3‐sn‐polyenylphosphatidylcholine (PPC) daily, orally for 2 months
Study: 2682593
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Org 3770 (ORG)
Study: 2682593
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg diazepam (DZ)
Study: 2682593
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AMI and DZ
Study: 2682593
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ORG and DZ
Study: 28973076
Drug: Lutein and
Normalized name: ICaps Lutein and Omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein and zeaxanthin dietary supplementation (2 daily capsules) for 6 months
Study: 28254122
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT-ON)
Study: 21112898
Drug: Optimal Medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Therapy (CRT-OFF)
Study: 15078238
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine patch (AP, 15 mg daily, n = 100)
Study: 15078238
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (PP, n = 100)
Study: 16966390
Drug: Ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1 mg/kg) plus midazolam (0.1 mg/kg; max: 2.5 mg)
Study: 16966390
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide (50%)/oxygen (50%) plus hematoma block (2.5 mg/kg of 1% buffered lidocaine)
Study: 1743624
Drug: CHOEP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOEP (cyclophosphamide 750 mg/m2 iv d 1, doxorubicin 50 mg/m2 iv d 1, vincristine 2 mg iv d 1, etoposide 100 mg/m2 iv d 3‐5, prednisolone 100 mg po d 1‐5)
Study: 1743624
Drug: hCHOP alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCHOP alternating with IVEP (cyclophosphamide 1200 mg/m2 iv d 1, doxorubicin 40 mg/m2 iv d 1 + 2, vincristine 2 mg iv d 1, prednisolone 100 mg po d 1‐5; ifosfamide 1500 mg/m2 iv d 1‐5, vindesine 3 mg/m2 iv d 1, etoposide 120 mg/m2 iv d 3‐5, prednisolone 100 mg po d 1‐5)
Study: 7075652
Drug: Alinidine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine 40 mg orally
Study: 26524223
Drug: Capacitive mode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capacitive mode of 448 kHz radiofrequency therapy
Study: 26524223
Drug: Resistive mode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistive mode of 448 kHz radiofrequency therapy
Study: 18640992
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (morphine 1 mg/ml, nalbuphine 0 mg/ml)
Study: 18640992
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (morphine 0.75 mg/ml, nalbuphine 0.25 mg/ml)
Study: 18640992
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (morphine 0.5 mg/ml, nalbuphine 0.5 mg/ml)
Study: 18640992
Drug: Group 4
Normalized name: Chlamydophila psittaci biogroup 4 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4 (morphine 0.25 mg/ml, nalbuphine 0.75 mg/ml)
Study: 18640992
Drug: Group 5
Normalized name: Chlamydophila psittaci biogroup 5 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 5 (morphine 0 mg/ml, nalbuphine 1 mg/ml)
Study: 12809966
Drug: Ritonavir 600
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir 600 mg
Study: 12809966
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg and Ritonavir 600 mg
Study: 1848170
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous injection of inulin (70 mg/kg over 5 min)
Study: 1848170
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection method
Study: 30986760
Drug: Coloxyl with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coloxyl with senna +20 ml lactulose BD commencing on day 3 (Regimen B)
Study: 30986760
Drug: Coloxyl with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coloxyl with senna tablets +20 ml lactulose BD commencing on day 6 (Regimen C)
Study: 17187586
Drug: ATI-7505 20
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-7505 20 mg t.i.d.
Study: 17187586
Drug: ATI-7505 10
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-7505 10 mg t.i.d.
Study: 17187586
Drug: ATI-7505 10
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-7505 10 and 20 mg t.i.d.
Study: 16318050
Drug: Lornoxicam (xefocam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (xefocam, 16 mg/day)
Study: 16318050
Drug: Ketorolac (ketanov,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (ketanov, 60-90 mg/day)
Study: 16318050
Drug: Ketoprofen/ketonal (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen/ketonal (200 mg/day)
Study: 16318050
Drug: Ketoprofen/artrozilene (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen/artrozilene (320 mg/day)
Study: 2366136
Drug: Penicillin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (10 million units intravenously) and tetracycline (0.25 g intramuscularly) for 12 hours
Study: 2366136
Drug: Penicillin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (10 million units intravenously) and tetracycline (0.25 g intramuscularly) for 12 hours followed by oral ampicillin (2 g) and tetracycline (1.5 g) per day for 60 hours
Study: 639708
Drug: Furosemide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (80 mg, single daily dose) given on the 12th, 13th, and 14th day of digoxin treatment
Study: 639708
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of furosemide with beta-methyl-digoxin
Study: 639708
Drug: Furosemide given
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide given ten hours after the last digoxin dose
Study: 31262691
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine treatment (group B2)
Study: 31262691
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group B1)
Study: 29045983
Drug: BATHE intervention
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BATHE intervention (daily for five days or until discharge)
Study: 25496178
Drug: BNO 1016
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNO 1016 (3 × 160 mg daily for 15 days)
Study: 25496178
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 × placebo daily for 15 days)
Study: 23808982
Drug: Apixaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months)
Study: 23808982
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (subcutaneous enoxaparin, followed by warfarin)
Study: 21981441
Drug: AWT(®) treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AWT(®) treatment with CELLACTOR(®) SC1 device, 8 sessions over 4 weeks
Study: 21981441
Drug: AWT(®) treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AWT(®) treatment
Study: 20112520
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (NaF) administered for 6 months prior to stapedectomy.
Study: 20112520
Drug: Stapedectomy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stapedectomy without sodium fluoride (NaF) administration.
Study: 11642675
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 400 mg/kg body weight, total 30-45 g, administered in the follicular phase of a planned pregnancy, with a booster dose upon pregnancy diagnosis.
Study: 8436740
Drug: Intravenous urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urokinase alone
Study: 8436740
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intravenous urokinase and rt-PA
Study: 26615328
Drug: Nanoliposomal irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanoliposomal irinotecan monotherapy
Study: 24849843
Drug: Response-adaptive randomization
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-adaptive randomization scheme with minimal sufficient balancing design for baseline covariates and a cap on treatment allocation ratio shift.
Study: 24849843
Drug: Control of
Normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control of important covariate imbalance and protection of treatment allocation randomness.
Study: 18481113
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CSA) 150 mg/m(2) orally to achieve trough levels of 120-180 ng/ml
Study: 18481113
Drug: Cyclophosphamide pulses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide pulses (CPH) 500 mg/m(2) per month intravenous
Study: 16136855
Drug: RSR13 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSR13 (100 mg/kg)
Study: 2251872
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine with pertussis toxoid
Study: 2251872
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine with pertussis toxoid and filamentous haemagglutinin
Study: 31091754
Drug: Collagen peptide
Normalized name: Procollagen peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen peptide supplementation (15 g daily)
Study: 22234928
Drug: Aripiprazole (ARIP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (ARIP; 5-30 mg/day)
Study: 22234928
Drug: Ziprasidone (ZIP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (ZIP; 40-160 mg/day)
Study: 17875084
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E at a dose of 100 mg/day for 3 months
Study: 16213237
Drug: Home-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based physical therapy (PT) group (n=13)
Study: 31532959
Drug: Polypill (atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, hydrochlorothiazide 12.5 mg)
Study: 21837534
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg once daily plus phloroglucinol
Study: 21837534
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg plus phloroglucinol
Study: 21837534
Drug: Phloroglucinol 240
Normalized name: phloroglucinol
DrugBank: Phloroglucinol (DB12944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phloroglucinol 240 mg daily (Control Group)
Study: 19671145
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (1-hour session, 4 times a week for 10 weeks) plus pharmacological therapy
Study: 19671145
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy only
Study: 17067857
Drug: Re-randomization for
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-randomization for optimal dosing
Study: 17067857
Drug: Re-randomization for
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-randomization for optimal dose-scheduling
Study: 17067857
Drug: Re-randomization for
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-randomization for salvage therapy
Study: 17067857
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of treatment trials
Study: 11737692
Drug: Griseofulvin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin (20 mg/kg/day for 6 weeks)
Study: 11737692
Drug: Terbinafine (>
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (> 40 kg: 250 mg; 20-40 kg: 125 mg; < 20 kg: 62.5 mg for 2-3 weeks)
Study: 11737692
Drug: Itraconazole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (5 mg/kg/day for 2-3 weeks)
Study: 11737692
Drug: Fluconazole (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (6 mg/kg/day for 2-3 weeks)
Study: 9415509
Drug: Lamotrigine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (400 mg)
Study: 3631772
Drug: Terbutaline inhaled
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhaled with a tube spacer
Study: 3631772
Drug: Terbutaline inhaled
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhaled without a tube spacer (conventional inhaler)
Study: 31076466
Drug: Online acceptance
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online acceptance and commitment therapy (ACT) intervention, 8 sessions over 8 weeks
Study: 25753087
Drug: Transdermal Fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal Fentanyl patches
Study: 21297553
Drug: Intensified dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified dosing (ID) regimen of enteric-coated mycophenolate sodium (EC-MPS) (2880 mg/day for days 0-14, 2160 mg/day for days 15-42, followed by 1440 mg/day)
Study: 21297553
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing (SD) regimen of enteric-coated mycophenolate sodium (EC-MPS) (1440 mg/day)
Study: 21297553
Drug: Intensified dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified dosing (ID) regimen of enteric-coated mycophenolate sodium (EC-MPS)
Study: 21297553
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing (SD) regimen of enteric-coated mycophenolate sodium (EC-MPS)